Title: Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal
cancer: A meta-analysis
Version: 1 Date: 28 May 2022
Reviewer's report:
Dear authors, thank you for your manuscript entitled "Efficacy and safety of anti-PD-1/PD-L1
therapy in the treatment of advanced colorectal cancer: A meta-anaylisis"
I find the quality of your manuscript good, the content clair and coherent, the linguistic style
adopted appropriate, with no major linguistic issues.
However, I will add some minor comments  to improve the quality of the manuscript:
- In the inclusion criteria (line 63): study investigating efficacy of anti PD-1/PD-L1.
However, you included also  combination studied of anti PD1 /PD-L1 + anti CTLA4.
Please specify in the inclusion criteria that combinational strategies with antiangiogenetic
treatments were admitted, since a possible impact on MSS subgroup has been highlighted and
remarked in the discussion .
- line 99 remove parenthesis OSR)
- I will add in the discussion a brief comment on toxicities with comparison with the main studies
of immunotherapy in lung and melanoma cancers (useful to clarify that they were stackable).
- Please add reference in line 169
- I suggest to read these articles and integrate them in your manuscript
El Jabbour T, et al. PD-L1 protein expression in tumour cells and immune cells in mismatch
repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142
antibody and whole section immunohistochemistry. J Clin Pathol. 2018 Jan;71(1):46-51. doi:
10.1136/jclinpath-2017-204525. Epub 2017 Jun 30. PMID: 28667193.
Valentini AM,  et al. PD-L1 expression in colorectal cancer defines three subsets of
tumor immune microenvironments. Oncotarget. 2018;9(9):8584-8596. Published 2018 Jan 12.
doi:10.18632/oncotarget.24196
- please correct by adding all the missing "t" in the PRISMA 2020 checklist.
Thank You
Dr. Claudia Parisi
Title: Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal
cancer: A meta-analysis
Version: 1 Date: 28 May 2022
Reviewer's report:
Dear authors, thank you for your manuscript entitled "Efficacy and safety of anti-PD-1/PD-L1
therapy in the treatment of advanced colorectal cancer: A meta-anaylisis"
I find the quality of your manuscript good, the content clair and coherent, the linguistic style
adopted appropriate, with no major linguistic issues.
However, I will add some minor comments  to improve the quality of the manuscript:
- In the inclusion criteria (line 63): study investigating efficacy of anti PD-1/PD-L1.
However, you included also  combination studied of anti PD1 /PD-L1 + anti CTLA4.
Please specify in the inclusion criteria that combinational strategies with antiangiogenetic
treatments were admitted, since a possible impact on MSS subgroup has been highlighted and
remarked in the discussion .
- line 99 remove parenthesis OSR)
- I will add in the discussion a brief comment on toxicities with comparison with the main studies
of immunotherapy in lung and melanoma cancers (useful to clarify that they were stackable).
- Please add reference in line 169
- I suggest to read these articles and integrate them in your manuscript
El Jabbour T, et al. PD-L1 protein expression in tumour cells and immune cells in mismatch
repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142
antibody and whole section immunohistochemistry. J Clin Pathol. 2018 Jan;71(1):46-51. doi:
10.1136/jclinpath-2017-204525. Epub 2017 Jun 30. PMID: 28667193.
Valentini AM,  et al. PD-L1 expression in colorectal cancer defines three subsets of
tumor immune microenvironments. Oncotarget. 2018;9(9):8584-8596. Published 2018 Jan 12.
doi:10.18632/oncotarget.24196
- please correct by adding all the missing "t" in the PRISMA 2020 checklist.
Thank You
Dr. Claudia Parisi
Please review this paper.
user
Title: Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal
cancer: A meta-analysis
Version: 1 Date: 28 May 2022
Reviewer's report:
Dear authors, thank you for your manuscript entitled "Efficacy and safety of anti-PD-1/PD-L1
therapy in the treatment of advanced colorectal cancer: A meta-anaylisis"
I find the quality of your manuscript good, the content clair and coherent, the linguistic style
adopted appropriate, with no major linguistic issues.
However, I will add some minor comments  to improve the quality of the manuscript:
- In the inclusion criteria (line 63): study investigating efficacy of anti PD-1/PD-L1.
However, you included also  combination studied of anti PD1 /PD-L1 + anti CTLA4.
Please specify in the inclusion criteria that combinational strategies with antiangiogenetic
treatments were admitted, since a possible impact on MSS subgroup has been highlighted and
remarked in the discussion .
- line 99 remove parenthesis OSR)
- I will add in the discussion a brief comment on toxicities with comparison with the main studies
of immunotherapy in lung and melanoma cancers (useful to clarify that they were stackable).
- Please add reference in line 169
- I suggest to read these articles and integrate them in your manuscript
El Jabbour T, et al. PD-L1 protein expression in tumour cells and immune cells in mismatch
repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142
antibody and whole section immunohistochemistry. J Clin Pathol. 2018 Jan;71(1):46-51. doi:
10.1136/jclinpath-2017-204525. Epub 2017 Jun 30. PMID: 28667193.
Valentini AM,  et al. PD-L1 expression in colorectal cancer defines three subsets of
tumor immune microenvironments. Oncotarget. 2018;9(9):8584-8596. Published 2018 Jan 12.
doi:10.18632/oncotarget.24196
- please correct by adding all the missing "t" in the PRISMA 2020 checklist.
Thank You
Dr. Claudia Parisi
assistant